Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
Sponsor: First Affiliated Hospital of Zhejiang University
Summary
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Official title: Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
Key Details
Gender
All
Age Range
20 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
152
Start Date
2026-01-01
Completion Date
2027-12-31
Last Updated
2025-12-29
Healthy Volunteers
No
Conditions
Interventions
18F-AlF-NOTA-Octreotide PET-CT or PET-MR
18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging